Recent Updates
Recently added Catalysts

Brensocatib

Phase 3FDA approved

Covid19 | Small Molecules | Infectious Disease |Insmed Incorporated|Trials Updated: Nov 4, 2026

Brensocatib development status

FDA approval on record Aug 12, 2025 as Brinsupri
Approval holderInsmed Inc
ApplicationNDA217673
Highest phase Phase 3
Registered trials 15 across 3 sponsors since Dec 2014

Label indication BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 ) FDA label

Brensocatib target and mechanism

Molecular targetCTSC
Target classInhibitor
ModalitySmall Molecules

Also known as Brensocatib Oral Solution, INS1007, AZD7986

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials8
Total Enrollment2,886

FDA Designations

No designations recorded

Brensocatib clinical trials

Brensocatib · 8 trials · 7 indications

Phase 3 2Phase 2 3Phase 1 3
NCT04817332STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19Covid19
COMPLETED406 Analytics
NCT04594369A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisNon-Cystic Fibrosis Bronchiectasis
COMPLETED1,767 Analytics
PHASE3COMPLETED
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
Covid19Unlock trial analytics
PHASE3COMPLETED
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis BronchiectasisUnlock trial analytics

Study Endpoints

Primary Endpoints

Comparison of Participant Clinical Status Between Treatment Arms
Up to 29 days

To determine the participant clinical status on a 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitation on activities; 3. Hospitalised, not requiring supplemental oxygen; 4. Hospitalised, requiring supplemental oxygen; 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death.

Annualized Rate of Pulmonary Exacerbations (PEs)
Up to Week 52

PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24
Baseline and Week 24
Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Cmax of Brensocatib on Day 28
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Tmax of Brensocatib on Day 28
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
AUC0-24 of Brensocatib in Plasma on Day 28
Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 28
Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
Up to Day 56

A TEAE is defined as any adverse event (AE) that occurred after the first dose of study investigational medicinal product (IMP) and within 28 days after the last dose of study IMP.

Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period
Baseline (Day 1) to Week 24

Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.

Area Under the Concentration Time Curve (AUC)
Pre-dose and at multiple timepoints post-dose on Days 1 to 9

Comparison of the pharmacokinetics of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.

Area Under the Plasma Concentration Time Curve (AUC) of Brensocatib
Pre-dose and at multiple timepoints post-dose on Days 1 to 14

Pharmacokinetics of brensocatib following a single dose will be assessed in participants with renal impairment and in healthy participants.

Maximum Observed Plasma Concentration (Cmax) of Brensocatib
Pre-dose and at multiple timepoints post-dose on Days 1 to 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Brensocatib
Pre-dose and at multiple timepoints post-dose on Days 1 to 14
Number of Participants who Experienced at Least one Adverse Event (AE)
Up to Day 14

Determination of the safety and tolerability of a single dose of brensocatib in participants with impaired renal function and in healthy participants.

Parts A and B: Number of Participants Who Experienced at Least One Adverse Event (AE)
Up to Day 61 in Part A and up to Day 11 in Part B

Determination and comparison of the safety and tolerability of INS1007 following single and multiple dose administration in Japanese and Caucasian participants.

Parts A and B: Area Under the Plasma Concentration-time Curve (AUC) of INS1007
Part A: Predose and at multiple time points postdose up to Day 33; Part B: Predose and at multiple time points postdose up to Day 11

Comparison of the pharmacokinetics of single and multiple doses of INS1007 in Japanese and Caucasian participants.

Secondary Endpoints

Improvement of One Category From Admission Using 7-point Ordinal Scale.
Day 29
Participant Clinical Status on 7-point Ordinal Scale
Day 15
Mean Change in the 7-point Ordinal Scale
Baseline to days 3, 5, 8, 11 and 29
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
BrensocatibEXPERIMENTALBrensocatib oral tablet, 25mg once per day for 28 days
PlaceboPLACEBO_COMPARATORPlacebo oral tablet, 25mg once per day for 28 days
Brensocatib 10 milligrams (mg)EXPERIMENTALParticipants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.
Brensocatib 25 mgEXPERIMENTALParticipants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.
Brensocatib 40 mgEXPERIMENTALParticipants received brensocatib 40 milligrams (mg) tablet, orally, once daily (QD) for 24 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
Brensocatib 10 mgEXPERIMENTALParticipants received brensocatib 10 mg tablet, orally, QD for 24 weeks along with MFNS by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
Cohort 1: BrensocatibEXPERIMENTALHealthy participants with normal hepatic function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with hepatic impairment.
Cohort 2: BrensocatibEXPERIMENTALParticipants with mild hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 3: BrensocatibEXPERIMENTALParticipants with moderate hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 4: BrensocatibEXPERIMENTALParticipants with severe hepatic impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 1 (Mild Impairment): BrensocatibEXPERIMENTALParticipants with mild renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 2 (Moderate Impairment): BrensocatibEXPERIMENTALParticipants with moderate renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 3 (Severe Impairment): BrensocatibEXPERIMENTALParticipants with severe renal impairment will receive single oral dose of brensocatib on Day 1 under fasted conditions.
Cohort 4 (Normal): BrensocatibEXPERIMENTALHealthy participants with normal renal function will receive single oral dose of brensocatib on Day 1 under fasted conditions. Healthy participants will be matched within the protocol criteria to one or more participants with renal impairment.
Part A: Cohort 1 (Dose 1)EXPERIMENTALJapanese and Caucasian participants will receive INS1007 at Dose 1 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
Part A: Cohort 2 (Dose 2)EXPERIMENTALJapanese and Caucasian participants will receive INS1007 at Dose 2 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
Part A: Cohort 3 (Dose 3)EXPERIMENTALJapanese and Caucasian participants will receive INS1007 at Dose 3 or matching placebo, orally, up to Day 30 in Part A under fasted conditions. Enrollment will commence in this cohort once the safety and tolerability data in Cohort 2 is deemed acceptable by the principal investigator (PI) and the Sponsor's medical monitor.
Part B: Treatment Sequence 1EXPERIMENTALJapanese and Caucasian participants will receive INS1007 at the dose established in Part A after a high-fat and high-calorie breakfast on Day 1 followed by a dose established in Part A on Day 8 under fasted conditions in Part B of the study.
Part B: Treatment Sequence 2EXPERIMENTALJapanese and Caucasian participants will receive INS1007 at the dose established in Part A under fasted conditions on Day 1 followed by dose established in Part A on Day 8 after a high-fat and high-calorie breakfast in Part B of the study.

Interventions

NameTypeDescription
BrensocatibDRUGSelective, competitive, and reversible inhibitor of DPP1
PlaceboDRUGMatched placebo
Brensocatib 10 mgDRUGOral tablet.
Brensocatib 25 mgDRUGOral tablet.
Mometasone furoate nasal spray (MFNS)DRUGNasal spray suspension.
INS1007DRUGOral tablets.
Unlock Study Design Details

Eligibility Criteria

Age Range16 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: 6.1. Inclusion criteria • Male or female * ≥16 years of age * SARS-CoV-2 infection (clinically suspected+ or laboratory confirmed\*). * Admitted to hospital as in-patient less than 96 hours prior to randomisation\^ * Illness of any duration, and at least one of the following: ...

Countries:United KingdomUnited StatesArgentinaAustraliaAustriaBelgiumBrazilBulgariaCanadaChileColombiaDenmarkFranceGermanyGreeceHungaryIrelandIsraelItalyJapanLatviaMalaysiaMexicoNetherlandsNew ZealandPeruPolandPortugalSerbiaSlovakiaSouth KoreaSpainTaiwanThailandTurkey (Türkiye)UkraineCzechiaSingapore
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 31, 2026NCT06013241Trial No Longer Active: was Completed

Frequently asked questions about Brensocatib

What is brensocatib?

Brensocatib is an investigational oral small molecule developed by Insmed Incorporated (ticker INSM). It is being studied in chronic rhinosinusitis without nasal polyps, cystic fibrosis, non-cystic fibrosis bronchiectasis, and other conditions. It is not approved and remains in clinical development.

What does brensocatib target?

Brensocatib targets CTSC, also known as cathepsin C. It is an inhibitor of this enzyme. By inhibiting CTSC, brensocatib is designed to reduce the activation of neutrophil serine proteases, which are involved in inflammatory responses.

Who makes brensocatib?

Brensocatib is developed by Insmed Incorporated, which trades on the Nasdaq under the ticker INSM. Insmed is the sponsor of the clinical trials evaluating brensocatib.

What phase is brensocatib in?

Brensocatib is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials. It is an investigational drug and has not been approved by the FDA for any indication.

What clinical trials is brensocatib in?

Brensocatib has been studied in completed trials including NCT06013241 in chronic rhinosinusitis without nasal polyps, NCT05673603 in renal impairment, NCT05517525 in hepatic impairment, and NCT05090904 in cystic fibrosis. These trials enrolled a total of 2,023 participants across multiple countries.

Is brensocatib the same as [14C]-brensocatib or brensocatib oral solution?

Yes, [14C]-brensocatib, brensocatib oral solution, and brensocatib 10 mg are alternative names or formulations of the same drug, brensocatib. The core drug name is brensocatib, developed by Insmed Incorporated.